Clinical Research Directory
Browse clinical research sites, groups, and studies.
Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors
Sponsor: TCRCure Biopharma Ltd.
Summary
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of functionally enhanced ALPP-targeted engineered T Cells (Herein referred to as Enhanced ALPP CAR-T) in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Official title: A Single-Arm, Single-Center, Open-Label Pilot Study of Functionally Enhanced ALPP-Targeted Engineered T Cells for Patients With ALPP-Positive Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-02-28
Completion Date
2029-02-28
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
Enhanced ALPP CAR-T treatment
Enhanced ALPP CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.
Locations (1)
The Jinling Hospital
Nanjing, Jiangsu, China